"Doctors in Beijing, remotely operating a surgical robotic arm in Qingdao, can complete the task of suturing the egg membrane. On April 17, the staff of Weigao Group pointed to the "Miaoshou S" surgical robot in the exhibition hall and introduced it to reporters.
Starting from an infusion set with meager profits and no competitiveness, Wego has grown step by step into a leader in China's medical device industry. Today, Weigao is deeply engaged in orthopedics, blood purification, clinical nursing, pharmaceutical packaging, minimally invasive intervention, surgery, blood transfusion, medical equipment, medical engineering and many other subdivisions, and its technology is at the advanced level of the same industry in China and even the same industry in the world.
10000-1=?In Wego, the answer to this question is "0". "Medical device products are related to every life, as long as there is one in 10,000 defects, it is a 100% failure. Sun Zhenlong, vice president of Weihai Research Institute of Weigao Group, said.
Innovation is the key driving force for the development of Wego. After more than ten years of research and development, Weigao has produced the third generation of biodegradable cardiac stents, becoming the first bioresorbable stent with independent intellectual property rights in China. The stent will gradually degrade into water and carbon dioxide after being implanted in the human body for about three years, and will be completely absorbed by the natural metabolism of the human body, which has obvious advantages compared with traditional metal stents. At present, the product has been successfully applied in more than 700 hospitals, benefiting more than 28,000 patients with coronary heart disease.
Weigao now has more than 1,000 varieties of medical devices and drugs, more than 200,000 specifications, and more than 1,500 patents. Break the foreign monopoly on more than 100 products such as high-end infusion consumables, polysulfone membrane dialyzers, orthopedic materials, prefillable syringes, indwelling needles, and blood transfusion consumables. In 2023, the Ministry of Industry and Information Technology of the People's Republic of China and the State Drug Administration will release the list of biomedical material innovation tasks (the first batch) of shortlisted units, and 8 products such as Weigao's medical polysulfone and zirconia composite alumina are shortlisted.
In July last year, the modern intelligent rehabilitation center jointly built by Weigao and Weihai Gao District Limin Hospital was completed and put into use, marking the beginning of Weigao's layout in the field of intelligent rehabilitation and promoting the rehabilitation field into the era of high-end intelligence. "In the future, Wego will continue to make efforts in medical devices, medical services and overall solutions for the medical system to actively benefit more patients. Sun Zhenlong said.
(Popular Daily, Popular News Client)